Research Article
Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide
Table 1
Baseline patient and disease characteristics.
| | Characteristic | Whole cohort (n = 153) | CRP/Alb <0.75 (n = 92) | CRP/Alb ≥0.75 (n = 61) | value |
| | Median age, y (range) | 59 (24–80) | 60 (34–80) | 57 (24–79) | 0.73 | | Age group, n (%) | | | | | | <50 years | 47 (30.7) | 30 (32.6) | 17 (27.9) | 0.24 | | ≥50 years | 106 (69.3) | 62 (67.4) | 44 (72.1) | | Gender, n (%) | | | | | | Female | 53 (34.6) | 32 (34.8) | 21 (34.4) | 0.83 | | Male | 100 (65.4) | 60 (65.2) | 40 (65.6) | | KPS, n (%) | | | | | | 90–100 | 93 (60.8) | 56 (60.9) | 37 (60.6) | 0.92 | | 70–80 | 60 (39.2) | 36 (39.1) | 24 (39.4) | | RTOG RPA class, n (%) | | | | | | III | 60 (39.2) | 41 (44.6) | 19 (31.1) | 0.19 | | IV | 63 (41.2) | 39 (41.3) | 24 (39.3) | | V | 30 (19.6) | 12 (18.5) | 18 (29.6) | | Symptom duration | | | | | | Median, mo (range) | 1.9 (0.3–5.9 | 2.0 (0.3–5.9) | 1.7 (0.3–4.4) | 0.62 | | <3 months, n (%) | 113 (73.9) | 69 (75.0) | 44 (72.1) | | ≥3 months, n (%) | 40 (26.1) | 23 (25.0) | 17 (27.9) | | Tumor location, n (%) | | | | | | Frontal | 37 (24.2) | 22 (23.9) | 15 (24.6) | 0.71 | | Parietal | 29 (19.0) | 18 (19.6) | 11 (18.0) | | Temporal | 34 (22.2) | 20 (21.7) | 14 (23.0) | | Occipital | 15 (9.8) | 9 (9.8) | 6 (9.8) | | Midline | 16 (10.5) | 10 (10.9) | 6 (9.8) | | Multilobar | 22 (14.3) | 13 (14.1) | 9 (14.8) | | Extent of surgery, n (%) | | | | | | Gross total | 54 (35.3) | 32 (34.8) | 22 (36.1) | 0.56 | | Subtotal | 74 (48.4) | 44 (47.8) | 30 (49.2) | | Biopsy | 25 (16.3) | 16 (17.4) | 9 (14.7) | | Corticosteroid use, n (%) | | | | | | Yes | 104 (68.0) | 62 (68.8) | 42 (67.4) | 0.80 | | No | 49 (32.0) | 30 (31.2) | 19 (32.6) | | Anticonvulsant use, n (%) | | | | | | Yes | 50 (32.7) | 29 (31.5) | 21 (34.4) | 0.48 | | No | 103 (67.3) | 63 (68.5) | 40 (65.6) | | Comorbid conditions, n (%) | | | | | | DM | 10 (6.5) | 6 (6.5) | 4 (6.6) | 0.91 | | HT | 7 (4.6) | 4 (4.3) | 3 (4.9) | 0.42 | | CAHD | 5 (3.3) | 3 (3.3) | 2 (3.3) | 0.98 | | COPD | 4 (2.6) | 2 (2.2) | 2 (3.3) | 0.39 | | CLD | 2 (1.3) | 1 (1.1) | 1 (1.7) | 0.48 |
|
|
CRP/Alb, CRP to albumin ratio; KPS, Karnofsky performance score; RTOG RPA, radiation therapy oncology group recursive partitioning analysis; DM, diabetes mellitus; HT, hypertension; CAHD, coronary artery heart disease; COPD, chronic obstructive lung disease; CLD, chronic liver disease.
|
